(News Bulletin 247) – The Janssen Pharmaceutical companies of Johnson & Johnson (J&J) announced yesterday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the marketing of ‘Akeega® (i.e. Niraparib + abiraterone acetate), in the form of a DAT (dual action tablet – double action pill) and in combination with prednisone or prednisolone, in the treatment of adults with resistant prostate cancer to metastatic castration (MCRPC) and BRCA1/2 mutations in whom chemotherapy is clinically indicated.
The laboratory recalls that prostate cancer is the most common cancer in men in Europe and that it remains a deadly disease, with high unmet needs in terms of treatment options.
“If this treatment option is approved, it could have an impact on the standard of treatment in force for men with MCRPC BRCA”, underlines Elena Castro, consultant oncologist at Octubon Universitaro Hospital, Institute of Investigation and Hospital 12 d’Octubre de Madrid, Spain.
The data show that niraparib combined with abiraterone acetate and prednisone reduced “significantly the risk of disease progression and death”, underlines the laboratory.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
